Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 87–88

HOS-109085 · Präparat HOS-093083

87 Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban AUC: ↑ 153% and Kaletra may increase (Ritonavir 600 mg twice Cmax: ↑ 55% rivaroxaban exposure which may daily) Due to CYP3A and P-gp increase the risk of bleeding. inhibition by lopinavir/ritonavir. The use of rivaroxaban is not recommended in patients receiving concomitant treatment with Kaletra (see section 4.4). Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose Edoxaban Edoxaban: reduction of the direct oral Serum concentrations may be anticoagulants (DOAC) should be increased due to Pgp inhibition by considered when a DOAC lopinavir/ritonavir. transported by P-gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co-administered with Kaletra. Anticonvulsants Phenytoin Phenytoin: Caution should be exercised in Steady-state concentrations was administering phenytoin with moderately decreased due to Kaletra. CYP2C9 and CYP2C19 induction Phenytoin levels should be by lopinavir/ritonavir. monitored when co-administering with Kaletra. Lopinavir: When co-administered with Concentrations are decreased due phenytoin, an increase of Kaletra to CYP3A induction by dosage may be envisaged. Dose phenytoin. adjustment has not been evaluated in clinical practice. Kaletra must not be administered once daily in combination with phenytoin. Carbamazepine and Carbamazepine: Caution should be exercised in Phenobarbital Serum concentrations may be administering carbamazepine or increased due to CYP3A phenobarbital with Kaletra. inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital levels should be monitored when Lopinavir: co-administering with Kaletra. Concentrations may be decreased When co-administered with due to CYP3A induction by carbamazepine or phenobarbital, an carbamazepine and phenobarbital. increase of Kaletra dosage may be envisaged. Dose adjustment has not been evaluated in clinical practice. Kaletra must not be administered once daily in combination with carbamazepine and phenobarbital. Lamotrigine and Lamotrigine: Patients should be monitored Valproate AUC: ↓ 50% closely for a decreased VPA effect Cmax: ↓ 46% when Kaletra and valproic acid or Cmin: ↓ 56% valproate are given concomitantly.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)